Drug Trial Radar · NCT06964113
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
Jun 11, 2025
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Eisai Korea Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.
Conditions
- Ulcerative Colitis
Interventions
Filgotinib MaleateDrug
Administered as oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Remission at Week 10 or 22Time frame: At Week 10 or 22
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Eisai Site #13
Busan, South Korea
Eisai Site #15
Busan, South Korea
Eisai Site #8
Busan, South Korea
Eisai Site #6
Daegu, South Korea
Eisai Site #2
Daejeon, South Korea
Eisai Site #16
Gyeonggi-do, South Korea
Eisai Site #4
Gyeonggi-do, South Korea
Eisai Site #11
Gyeongnam, South Korea
Eisai Site #18
Jungnam, South Korea
Eisai Site #7
Jungnam, South Korea
Eisai Site #10
Seoul, South Korea
Eisai Site #12
Seoul, South Korea
Eisai Site #14
Seoul, South Korea
Eisai Site #17
Seoul, South Korea
Eisai Site #19
Seoul, South Korea
Eisai Site #1
Seoul, South Korea
Eisai Site #3
Seoul, South Korea
Eisai Site #5
Seoul, South Korea
Eisai Site #9
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.